Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Rapid diagnostics

New system simultaneously detects antibiotic resistence and virulence of K. pneumoniae

Now, a research team has developed a novel diagnostic approach that enables the rapid and simultaneous detection of both antibiotic resistance and high virulence in Klebsiella pneumoniae.

News • When good bacteria fight back

Klebsiella strain to protect against IBD gut infections

New research shows that a harmless strain of Klebsiella – discovered by chance in laboratory experiments – can eliminate infections and reduce gut inflammation in inflammatory bowel disease (IBD).

News • Standardized assessment criteria

Lost in translation: ICU experts call for universal severity score

Current scores to assess the severity of illness in ICU patients often fail in international contexts. Researchers now call for a global scoring system based on universally available data.